Retatrutide's Trial Data Is Genuinely Remarkable — Here's the Actual Numbers

Retatrutide has generated an enormous amount of online discussion, much of it flattened into "better than Ozempic" claims that skip past the actual numbers. The real trial data is genuinely strong, and worth presenting on its own terms. The data comes from TRIUMPH-1, a real Phase 3 trial involving 2,339 patients over 80 weeks. The 12 milligram dose group averaged 28.3 percent weight loss. The more striking figure: 45.3 percent of patients on that 12 milligram dose lost 30 percent or more of their total body weight, a result in the range typically associated with bariatric surgery rather than a medication. A second trial, TRANSCEND-T2D-1, studied patients with type 2 diabetes and reported a 2.0 percentage point reduction in HbA1c alongside 16.8 percent weight loss across 537 patients. There is also an early sleep apnea substudy nested inside TRIUMPH-1 reporting positive results, suggesting the compound's effects may extend beyond weight loss alone. The important caveat: Retatrutide is not FDA approved and is not available by prescription as of 2026. Eli Lilly has the primary efficacy dataset needed for a New Drug Application filing, expected before the end of the year, but a filing is not an approval. The real data here is strong enough to stand on its own without the hype-driven framing it usually gets online. It just is not, yet, an approved, prescribable medication.